![Peter A. Petillo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter A. Petillo
Plus aucun poste en cours
Profil
Peter A.
Petillo is the founder of Deciphera Pharmaceuticals, Inc. (founded in 2003).
He previously worked as a Principal Scientist at NeoGenesis Pharmaceuticals, Inc. and as a Principal at Whitehead Institute for Biomedical Research.
Petillo earned a doctorate degree from the University of Wisconsin in 1991 and an undergraduate degree from the University of New Hampshire in 1985.
Dr. Petillo is also the founder of Deciphera Pharmaceuticals LLC.
Anciens postes connus de Peter A. Petillo
Sociétés | Poste | Fin |
---|---|---|
DECIPHERA PHARMACEUTICALS, INC. | Fondateur | - |
NeoGenesis Pharmaceuticals, Inc.
![]() NeoGenesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeoGenesis Pharmaceuticals, Inc. used to discover and develop small molecule drugs. The company was founded in 1997 by Allen H. Michels and was headquartered in Cambridge, MA | Corporate Officer/Principal | - |
Whitehead Institute for Biomedical Research
![]() Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Deciphera Pharmaceuticals LLC
![]() Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Fondateur | - |
Formation de Peter A. Petillo
University of New Hampshire | Undergraduate Degree |
University of Wisconsin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 4 |
---|---|
Deciphera Pharmaceuticals LLC
![]() Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
NeoGenesis Pharmaceuticals, Inc.
![]() NeoGenesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeoGenesis Pharmaceuticals, Inc. used to discover and develop small molecule drugs. The company was founded in 1997 by Allen H. Michels and was headquartered in Cambridge, MA | Health Technology |
Whitehead Institute for Biomedical Research
![]() Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Commercial Services |
Deciphera Pharmaceuticals, Inc.
![]() Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |